VIPIVOTIDE TETRAXETAN
Genital Neoplasms, Male
Australian and New Zealand Urogenital and Prostate Cancer Trials GroupSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Genital Neoplasms, Male cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
STI571 Novartis Pharmaceuticals | Phase 2 | B |
PSMA-HBED-CC ALF-18 Alessandro D'Agnolo | Phase 2 | B |
IMIFOPLATIN Promontory Therapeutics Inc. | Phase 2 | CCC |
Ixabepilone Cedars-Sinai Medical Center | Phase 2 | CCC |
Ipilimumab Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Phase 2 | CCC |
View all 14 →
Same molecule, other indications
VIPIVOTIDE TETRAXETAN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →